Tagged with r&d

Austria Prof. Ruth Ladenstein, executive director of the Medicines for Children Research Organisation (OKIDS) in Austria, explains OKIDS’ drive to ensure drugs are paediatric specific by conducting child-specific clinical trials. Furthermore, she highlights the challenges associated with achieving a participating child’s consent and defines what must be done to gain governmental…

Canada Roseann O’Reilly Runte, president of the Canada Foundation for Innovation (CFI) speaks about the role and the importance of innovation in the Canadian life sciences industry and how Canada is a global leader in a number of areas. Given your diverse background, can you tell our international audience about your…

Austria Michael Stampfer, managing director of the Vienna Science and Technology Fund (WWTF), the only private, non-profit organization in Vienna dedicated to funding scientific research, discusses the challenges scientific research faces in Austria and how the organization helps bridge the gap between academia and industry. Furthermore, he illustrates the steps taken…

Austria Heidrun Katholnigg, executive director of global clinical development Europe for Celerion, a global CRO that specialises in phase I, II and III clinical trials, discusses the acquisition of Assign Group by Celerion in 2016 and the importance of Austria in managing European clinical operations. Furthermore, she highlights the favourable clinical…

Switzerland Saad Harti, president of Legacy Healthcare, discusses the company’s origins, their unique focus on side-effect free botanical drugs for chronic conditions, and the importance of stakeholder education in this exciting but still immature field.   Most of our current emphasis is on alleviating side effects of cancer treatments, also called…

Austria Dr. Dietmar Katinger, CEO of Polymun, an Austrian R&D and contract manufacturing company, discusses the challenges CMO companies face within the Austrian market and increasing industry regulations. He also provides an overview of Austria’s ability to accelerate its stature as an innovation hub. Could you introduce the scope of the…

Austria Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop of economic stability. “Austria should be proud of the abundance…

Brazil Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over the past few years as well as his vision to propel the development of pharmaceutical sciences in the country. What…

Colombia Dr. Sanjay Machado, the Vice President of Global Operations and Integrations for JSS Medical Research Inc., (JSS) a Canadian based international Contract Research Organisation, elaborates on the rapid expansion of the company through strategic acquisitions, the full range of clinical research-related services of JSS and the company’s vision to expand…

Austria Dr. Kurt Zatloukal, national node director of the Bio-Banking and Bio-Molecular Resources Research Infrastructure of Austria (BBMRI Austria), discusses the challenges of collaboration between the private and academic pharmaceutical sectors and the importance of their work in advancing pharmaceutical innovation. Furthermore, he looks into the growing trend of personalised medicines…

Colombia Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment to continue advancing the therapeutic value of care and the clinical research landscape in Colombia. With 70 years of presence…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…